These results indicate that in naturally HER2/ER-expressing tumours, increased oestrogen signalling may occur as a result of inhibiting the growth factor signalling pathway and, conversely, increased growth factor signalling may result as a consequence of inhibiting oestrogen signalling. The gene discussed is ESR1; the disease is neoplasm.